Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated interferon alfa-2a + entecavir
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Pegylated interferon alfa-2a + entecavir is a combination therapy used for the treatment of chronic hepatitis B (CHB). Pegylated interferon alfa-2a is a long-acting interferon that acts as an immunomodulator and antiviral agent by binding to the type I interferon receptor (IFNAR), triggering the JAK-STAT signaling pathway and inducing the expression of antiviral genes. Entecavir is a guanosine nucleoside analogue that potently inhibits the hepatitis B virus (HBV) polymerase (reverse transcriptase) by competing with the natural substrate deoxyguanosine triphosphate, thereby blocking viral DNA synthesis. This specific combination and sequential regimen have been studied by Huashan Hospital in multicenter prospective trials to evaluate their ability to induce HBsAg seroclearance in patients who have already achieved viral suppression under long-term entecavir monotherapy.
- Brand names
- PegasysBaraclude
- Other names
- PegIFN alfa-2a + ETVPegylated interferon alfa-2a plus Entecavir
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on pegylated interferon alfa-2a + entecavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated interferon alfa-2a + entecavir.